share_log
Breakings ·  Dec 8 07:15
Syndax Presents Positive Revuforj® (Revumenib) Data in Acute Leukemias From Multiple Trials, Including the Save Combination and Augment-101 Trials, at 66TH Ash Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment